Recombinant human monoclonal antibody expressed in CHO binding to human KIRD2 subgroup. It is a human monoclonal antibody designed for the treatment of cancer.
Figure 1 Anti-KIRD2 Subgroup Antibody (Lirilumab) (TAB-757) in ELISA
ELISA analysis of TAB-757 was performed by coating with KIR2DL1 Protein, Human, Recombinant (His Tag).
Blue line: TAB-757
Red line: Negative control
Figure 2 Anti-KIRD2 Subgroup Recombinant Antibody (TAB-757) in SDS-PAGE
SDS-PAGE analysis of TAB-757 in non-reduced (Lane 1) and reduced (Lane 2) conditions.
Figure 3 Anti-KIRD2 Subgroup Recombinant Antibody (TAB-757) in HPLC
HPLC analysis of TAB-757 shows the purity is>95%.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1602-sdAb | Recombinant Anti-Human KIRD2 VHH Single Domain Antibody | WB, ICC, ChiP, FA, ELISA | Llama VHH |
There are currently no Customer reviews or questions for TAB-757. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-757, RRID: AB_3112004)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.